SkyMirr

At SkyMirr, we are developing Radio Frequency technology and products across multiple industries, including broadband wireless access and medical devices. We plan to use short-term revenue from the broadband wireless market to fund our long-term development of innovative cancer treatment. We are currently pre-market, with real customers already placing initial orders. We have multiple patents pending and more groundbreaking products in development.

Select this bonus

$298+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.




Select this bonus

Friends and Family Early Birds
Invest within the first 72 hours and receive 25% bonus shares




2
days

12
hours

41
mins

25
secs





Select this bonus

$500+ Investment
$500+ Receive 2% bonus shares


Select this bonus

$1,000+ Investment
$1,000+ Receive 4% bonus shares


Select this bonus

$2,500+ Investment
$2,500+ Receive 8% bonus shares


Select this bonus

$5,000+ Investment
$5,000+ Receive 10% bonus shares


Select this bonus

$10,000+ Investment
$10,000+ Receive 15% bonus shares and a Zoom Call with the Founders


Select this bonus

$25,000+ Investment
$25,000+ Receive 20% bonus shares and a Zoom Call with the Founders


Select this bonus

$50,000+ Investment
$50,000+ Receive 25% bonus shares and a Zoom Call with the Founders, as well as receive quarterly business update materials from the top management.

We have developed RF technology with many key applications across multiple industries, and we are engaging in opportunities for both short-term and long-term growth.

The global 5G RF/antenna market was valued at $280.2 million as of 2020 and is growing at a CAGR of 54.7% (Source). Meanwhile, the cancer therapy market was valued at $158 billion in 2020, with a CAGR of 9.15% (Source).

We already have an agreement in place with CCL Group to supply innovative advanced RF technology products to improve wireless communication and performance across 21 countries in East and Central Africa (Source). We've also received our first PO from SB-Solutions for RF-based biomedical products.

Dr. Frank (Taeho) Son, Ph.D.



Chief Scientist


Over 30 years of experience in RF/Antenna/Medical areas as an academic/industrial leader such as Professor of Soonchunhyang University, Senior researcher in LGE, and Chairman of ITS (Intelligent Transportation System), the honored academic institute in Korea. Published over 316 papers and 34 patents. Ph.D. in Electronic Communication Engineering from Hanyang University















Richard Janney



Chief Financial Officer


Over 25 years of experience in finance/accounting leadership positions such as CFO and VP of Finance in companies in multiple industries including Trident Microsystems and Skye Bioscience. Currently serving Bluestar Genomics as CFO. Richard helped raise over $100M in venture and secondary offerings, taken companies through IPO, completed M&A transactions valued at ~$500M, and expanded global operations.